Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B

• Published in: The New England journal of medicine Vol. 391; no. 22; pp. 2098 - 2109
• Main Authors: Hou, Jinlin, Zhang, Wenhong, Xie, Qing, Hua, Rui, Tang, Hong, Morano Amado, Luis Enrique, Yang, Sheng-Shun, Peng, Cheng-Yuan, Su, Wei-Wen, Chuang, Wan-Long, Kim, Dong Joon, Avihingsanon, Anchalee, Kao, Jia-Horng, Leerapun, Apinya, Yuen, Man-Fung, Asselah, Tarik, Liang, Xieer, Bo, Qingyan, Canducci, Filippo, Catanese, Maria Teresa, Chen, Ethan, Cheng, Cong, Chughlay, Farouk, Das, Sudip, Glavini, Katerina, Guerreiro, Nelson, Huang, Yan, Kakrana, Priyanka, Kazma, Rémi, Patil, Avinash, Pavlovic, Vedran, Surujbally, Bernadette, Triyatni, Miriam, Upmanyu, Ruchi, Wat, Cynthia, Gane, Edward
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 05.12.2024
• Subjects: Adult; Adverse events; Alanine transaminase; Antigens; Antiviral Agents - administration & dosage; Antiviral Agents - adverse effects; Chronic infection; Clinical significance; Drug dosages; Drug Therapy, Combination - adverse effects; Drug Therapy, Combination - methods; Female; Gastroenterology; Gastroenterology General; Genetics; Genetics General; Global Health; Hepatitis B; Hepatitis B surface antigen; Hepatitis B Surface Antigens - blood; Hepatitis B virus - drug effects; Hepatitis B virus - genetics; Hepatitis B virus - immunology; Hepatitis B, Chronic - blood; Hepatitis B, Chronic - drug therapy; Hepatitis B, Chronic - immunology; Humans; Immunomodulating Agents - administration & dosage; Immunomodulating Agents - adverse effects; Immunomodulation; Immunomodulators; Infections; Infectious Disease; Infectious Disease General; Interferon-alpha - administration & dosage; Interferon-alpha - adverse effects; Liver cancer; Liver cirrhosis; Liver Disease; Male; Middle Aged; Nucleoside analogs; Nucleosides - administration & dosage; Nucleosides - adverse effects; Nucleosides - analogs & derivatives; Nucleotide analogs; Polyethylene Glycols - adverse effects; Polyethylene Glycols - therapeutic use; Recombinant Proteins - administration & dosage; Recombinant Proteins - adverse effects; RNA Therapeutics; RNA viruses; RNA, Small Interfering - administration & dosage; RNA, Small Interfering - adverse effects; Seroconversion; siRNA; Treatment Outcome; Viral Infections; α-Interferon
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa2405485

In a phase 2 trial involving participants taking a nucleoside or nucleotide analogue, 23% of those assigned to receive xalnesiran plus pegylated interferon alfa-2a had HBsAg loss at 24 weeks after the end of treatment.